Claims for Patent: 11,597,692

Summary for Patent: 11,597,692

Title:	Process for preparing tapinarof
Abstract:	The present invention provides processes for the preparation of 3, 5-Dihydroxy-4-isopropyl-trans-stilbene or a salt or solvate thereof and novel intermediates used therein. In some embodiments the 3, 5-Dihydroxy-4-isopropyl-trans-stilbene is prepared from (E)-2-chloro-2-isopropyl-5-styrylcyclohexane-1,3-dione. Also disclosed are crystal forms of 3, 5-Dihydroxy-4-isopropyl-trans-stilbene or a salt or solvate thereof and pharmaceutical compositions comprising same.
Inventor(s):	Ian Paul Andrews, Nicholas CALANDRA, Tyler Andrew DAVIS, Ravinder Reddy Sudini
Assignee:	Dermavant Sciences GmbH , GlaxoSmithKline Intellectual Property Development Ltd
Application Number:	US17/174,566
Patent Claims:	1. A pharmaceutical composition comprising: a compound consisting of at least 99% by weight of a compound of Formula (I) wherein the compound is at least 95% form 1, characterized by an X-ray powder diffraction pattern having peaks at 15.0, 17.8, 19.1, 20.2, 21.5, 22.4, 23.3, 24.5, 26.2 and 27.9 degrees2θ (±0.1° 2θ); and less than or equal to 1% impurities; wherein the impurities include at least a compound of the Formula and a pharmaceutically acceptable excipient. 2. A process for preparing the compound of the composition of claim 1, comprising crystallizing a compound of Formula (I) using methanol and water. 3. The process of claim 2, wherein the process comprises seeding. 4. The compound of the composition of claim 1 prepared by a process comprising crystallizing a compound of Formula (I) using methanol and water. 5. A compound of Formula (I) or a salt or solvate thereof; wherein the compound or a salt or solvate thereof, is at least 99% pure by weight and wherein the compound is at least 95% form 1 characterized by an X-ray powder diffraction pattern having peaks at 15.0, 17.8, 19.1, 20.2, 21.5, 22.4, 23.3, 24.5, 26.2 and 27.9 degrees2θ (±0.1° 2θ); prepared by a process comprising: a) decarboxylating a compound of Formula (VI) in the presence of a base selected from trimethylamine, imidazole, pyridine, and lutidine (2,6-dimethylpyridine) to form a compound of Formula (V) or a salt thereof b) esterifying the compound of Formula (V) or a salt thereof with methanol and aqueous hydrochloric acid to form a compound of Formula (IVa) c) cyclizing the compound of Formula (IVa) with potassium tert-butoxide to form a compound of Formula (III) d) halogenating the compound of Formula (III) with a halogenating agent selected from 1,3-dichloro-5,5-dimethylhydantoin, N-chlorosuccinimide, and trichloroisocyanuric acid, to form a compound of Formula (IIa) and e) aromatizing the compound of Formula (IIa) in the presence of an additive reagent selected from tetrabutylammonium bromide, benzyltriethylammonium chloride, tetrabutylammonium chloride, tetraethylammonium chloride, to form the compound of Formula (I) or a salt or solvate thereof. 6. The compound of claim 5, wherein the compound is about 96% form 1. 7. The compound of claim 5, wherein the compound is about 97% form 1. 8. The compound of claim 5, wherein the compound is about 98% form 1. 9. The compound of claim 5, wherein the compound is about 99% form 1. 10. The compound of claim 5, wherein the compound is at least 99% form 1. 11. The compound of claim 5, wherein the process further comprises: f) crystallizing the compound of Formula (I) using methanol and water. 12. The compound of claim 11, wherein the crystallizing comprises seeding.